Study Highlights Increased Risks of Oral Hormone Therapy for Women with Type 2 Diabetes
A recent study emphasizes the increased cardiovascular risks linked to oral hormone replacement therapy in women with type 2 diabetes, highlighting transdermal options as safer alternatives.
Recent research presented at the European Association for the Study of Diabetes (EASD) meeting in Vienna has shed light on the potential cardiovascular risks associated with hormone replacement therapy (HRT) in women with type 2 diabetes (T2D). While skin patch HRT was not linked to a higher risk of blood clots or stroke, oral HRT was associated with significant concerns.
In women with T2D, those using oral HRT showed a doubled risk of developing a pulmonary embolism (PE)—a dangerous blood clot in the lungs—and faced a 21% increased chance of heart disease compared to women using transdermal (skin patch) HRT. Conversely, transdermal HRT did not demonstrate an increased risk for PE, stroke, or cancers related to estrogen.
The study analyzed electronic health records from the TriNetX database, including 36,855 women aged around 59 years, who initiated HRT or statins between 2000 and 2020, with five years of follow-up. The data revealed that women with T2D on HRT, particularly oral formulations, faced higher risks of deep vein thrombosis (DVT), stroke, and cardiovascular disease.
Researchers emphasized that the increased risks observed with oral HRT might stem from how estrogen is processed in the body. Oral estrogen undergoes extensive liver metabolism, potentially disrupting the balance of clotting factors, whereas skin patches deliver estrogen directly, with lower doses.
Lead researcher Dr. Matthew Anson noted, "Our findings suggest transdermal HRT appears safer for women with T2D, and oral estrogen therapy should be prescribed with caution." Given these findings, healthcare providers are encouraged to consider the route of HRT administration carefully, especially for women managing T2D.
Despite the valuable insights, the study's retrospective nature means other unmeasured factors could influence the results. The majority of participants were white women, which may limit applicability across diverse populations. Further research is essential, but these results offer important guidance for clinical decision-making in menopause management for women with T2D.
For now, women with T2D and menopausal symptoms should consult their healthcare providers about the safest HRT options tailored to their individual health profiles.
(Source: https://medicalxpress.com/news/2025-09-women-diabetes-oral-hormone-therapy.html)
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Study Finds Cycling May Offer Greater Brain Health Benefits Than Walking
Discover how cycling as a daily activity may reduce the risk of dementia and support brain health, based on recent research involving hundreds of thousands of adults.
Emerging Evidence on Blood Thinner Use Following Coronary Stenting
New research from the ESC Congress 2025 examines the safety and effectiveness of early aspirin withdrawal and P2Y12 inhibitor monotherapy after coronary stenting, highlighting potential benefits in bleeding reduction without significantly increasing ischemic risk.
Study Reveals Immune Pathway in Joint Tissue Linked to Early Rheumatoid Arthritis
New research uncovers the role of immune proteins and bacterial remnants in early rheumatoid arthritis, paving the way for improved diagnosis and treatment strategies.
Targeting the Brain: A New Approach to Treating Type 2 Diabetes
Emerging research indicates that neural pathways, specifically AgRP neurons in the hypothalamus, may be key targets for innovative treatments of type 2 diabetes, beyond conventional methods focused on obesity and insulin resistance.